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Abstract
Uncontrolled asthma is a risk factor for pregnancy-related complications. Hyaluronic acid (HA), a potential peripheral blood
marker of tissue fibrosis in various diseases, promotes eosinophil survival and plays a role in asthmatic airway inflammation
as well as in physiological processes necessary to maintain normal pregnancy; however the level of circulating HA in asthma
and asthmatic pregnancy is unknown. We investigated HA levels in asthmatic patients (N= 52; asthmatic pregnant (AP)
N= 16; asthmatic non-pregnant (ANP) N= 36) and tested their relationship to asthma control. Serum HA level was lower in
AP than in ANP patients (27 [24.7–31.55] vs. 37.4 [30.1–66.55] ng/mL, p = 0.006); the difference attenuated to a trend after its
adjustment for patients’ age (p = 0.056). HA levels and airway resistance were positively (r = 0.467, p = 0.004), HA levels and
Asthma Control Test (ACT) total score inversely (r =20.437, p = 0.01) associated in ANP patients; these relationships
remained significant even after their adjustments for age. The potential value of HA in the determination of asthma control
was analyzed using ROC analysis which revealed that HA values discriminate patients with ACT total score $20 (controlled
patients) and ,20 (uncontrolled patients) with a 0.826 efficacy (AUC, 95% CI: 0.69–0.97, p = 0.001) when 37.4 ng/mL is used
as cut-off value in ANP group, and with 0.78 efficacy (AUC, 95% CI: 0.65–0.92, p = 0.0009) in the whole asthmatic cohort. In
conclusion circulating HA might be a marker of asthma control, as it correlates with airway resistance and has good
sensitivity in the detection of impaired asthma control. Decrease of HA level in pregnancy may be the consequence of
pregnancy induced immune tolerance.
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Introduction
Asthma is a chronic inflammatory disease of the airways
characterized by variable and recurring symptoms, local inflam-
mation, reversible airflow obstruction, and bronchospasm [1].
Asthma is a prevalent chronic disease which is not optimally
controlled in about 50% of cases even in developed countries. It
has a high burden of morbidity especially if not controlled [2];
however, objective serum markers reflecting asthma control are
not known.
Airway inflammation, a major element of asthma pathophys-
iology, has been described to be related to asthma severity [3,4]
and asthma control [5] and causing systemic signs of inflammation
as well [1]. Easily obtainable markers of systemic inflammation
especially those related to clinical control of asthma may help in
clinical decision-making. Recently, a number of studies investi-
gated the sensitivity of circulating inflammatory markers in the
evaluation of asthma control. Increase in proinflammatory
cytokines, such as interleukin-6 [6] and tumor necrosis factor-a
[7,8] have already been described in asthmatic patients as well as
elevated circulating C-reactive protein levels in nonallergic [9],
and neutrophilic asthma [10]. In steroid-naive asthmatic patients
C-reactive protein levels negatively correlated with indices of lung
function (forced expiratory volume in one second (FEV1), FEV1/
forced vital capacity and forced mid-expiratory flow) and positively
with sputum eosinophil count [11]. In our recent study another
inflammatory biomarker, serum soluble urokinase plasminogen
activator receptor (suPAR) was shown to correlate with airway
resistance having a good sensitivity in the detection of impaired
asthma control [12].
Asthma is one of the most frequent potentially serious medical
conditions complicating pregnancy, occurring in 3.7 to 8.4 percent
of pregnant women [13]. It is a risk factor for several obstetrical
and fetal complications including preeclampsia, Cesarean section,
preterm delivery, low birth weight and a high risk of perinatal
mortality [14–16]. In addition, pregnancy has also an effect on
asthma control deteriorating the symptoms in one-third of
pregnant women [17]; therefore, monitoring and treatment of
pregnant women with asthma is a particular challenge. Optimal
asthma control during pregnancy decreases maternal and neonatal
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risks [18]; hence non-invasive assessment of asthma control and
appropriate management is of particular importance. However,
although some clinical factors (such as more severe asthma before
pregnancy, disease worsening in previous pregnancies [15,17,19]
and impaired asthma-specific quality of life in early pregnancy
[20] may predict the changes of asthma control during pregnancy,
to date systemic markers related to asthma control determinants or
any lung function parameters in asthmatic pregnancy are missing.
During last decades elevated serum level of hyaluronan
(hyaluronic acid; HA), a major extracellular matrix component,
was reported in several pathological conditions characterized by
systemic inflammation and activation of immune system (e.g.
sepsis, rheumatoid arthritis); however its suitability as a systemic
inflammation marker in asthma has not yet been investigated. HA
is a glycosaminoglycan forming non-covalent complexes with
extracellular matrix proteoglycans [21,22]. It is a structural
building molecule of many healthy tissues which degrades to low
molecular weight HA during pathological conditions such as
immune activation [23], systemic inflammation [24], tissue injury
and repair [25], and further stimulates chemokines, cytokines,
adhesion molecules, transcription- and growth factors, activate
fibroblasts, epithelial- and inflammation cells thus generating
proinflammatory and proangiogenic effects [26]. Normal serum
concentration of HA may vary from 10 to 100 mg/L [27].
According to available data, inflammatory response leads to
elevated circulating HA in many inflammatory conditions, such as
liver and pulmonary fibrosis, atherosclerosis, diabetes, certain
tumors, chronic obstructive pulmonary disease [28].
Recently HA was shown to be implicated in asthma
pathophysiology by contributing to the two main characteristics
of the disease: airway inflammation and remodeling. Elevated
levels of HA have been reported in bronchoalveolar lavage fluid of
persistent asthmatic patients [29,30] and they correlated with the
severity of disease [31]. A recent study has shown decreased
elimination and increased responsiveness to HA in asthmatic
macrophages which may lead to persistent airway inflammation
[32]. In addition, HA promotes eosinophil survival in a dose-
dependent manner that may play a further role in chronic
asthmatic inflammation [33].
HA also plays a role in maintaining healthy pregnancy [34].
Serum HA levels increase near term, reflecting the process of
cervical ripening [35]. Furthermore, two studies indicated HA to
be a predictive marker of preeclampsia in the late pregnancy
[36,37]. However, despite of the known role of HA in the
mechanism of asthma and pregnancy, as well as findings in
bronchoalveolar lavage fluid, airway smooth muscle and endo-
bronchial biopsy, to date data on circulating HA levels and their
possible relationship to disease control are scarce either in asthma
or in asthmatic pregnancy.
Therefore, present study aimed to investigate serum HA levels
in patients with asthma and asthmatic pregnancy. Furthermore, in
order to define the utility of HA as a screening tool in the
evaluation of asthma control in asthmatic pregnant and non-
pregnant patients, we also investigated the relationship between
HA and asthma control determinants.
Methods
Ethics Statement
Written informed consent was obtained from all subjects, and our
study was reviewed and approved by an independent ethical
committee of the institution (Institutional and Regional Research
Ethics Committee of Semmelweis Medical University). Laboratory
studies and interpretations were performed on coded samples
lacking personal and diagnostic identifiers. The study was adhered
to the tenets of the most recent revision of the Declaration of
Helsinki.
Study Participants
The study had a cross-sectional design. 36 asthmatic non-
pregnant (ANP) women and 16 asthmatic pregnant (AP) patients
were enrolled. Asthmatic patients were assessed at their regular visit
at the outpatient clinic of the Department of Pulmonology,
Semmelweis University. They had persistent disease and asthma
had been diagnosed according to the current guidelines (at least 6
months prior to the study) [1]. Exclusion criteria were diabetes
mellitus, autoimmune disease, cardiovascular diseases, renal disor-
der, liver diseases, untreated hypertensive disorder, angiopathy,
maternal or fetal infection, fetal congenital anomaly, multi-fetal
gestation, current smoking or more than 5 pack years of smoking
history, any other chronic disease (except for allergic rhinitis), and
acute infection within four weeks of measurement. Patients were
asked not to use their medication 12 hours before visits.
Measurement of Serum Hyaluronan
Plasma was isolated from EDTA anticoagulated fasting blood
samples and stored at 280uC until measurement. Serum
hyaluronan was determined by enzyme-linked binding protein
assay (Corgenix, Inc., Broomfield, Co, USA).
Lung Function Measurement and Asthma Control
Evaluation
Lung function was measured by means of electronic spirometer
(PDD-301/s, Piston, Budapest, Hungary) according to the
American Thoracic Society guidelines [38]. Three technically
acceptable maneuvers were performed and the best was used.
Forced expiratory volume in one second (FEV1), peak expiratory
flow rate (PEF), and airway resistance (Raw) were measured.
Asthma control was assessed using the Asthma Control Test
(ACT) recommended by the current guideline [1].
Statistics
Statistical analysis was performed using Graph Pad Prism
software 5 (GraphPad Software, La Jolla, CA, USA), correction
for age was made by SPSS Statistics V21 (International Business
Machines Corporation, NY, USA). Data distribution was analyzed
by D’Agostino-Pearson normality test. Data are expressed as
median [interquartile range] except for the normally distributed
values of age which are presented as the mean with standard
deviation (SD). We used unpaired Student’s t-test for comparisons
between the study groups with Welch correction for the
adjustment for age. In case of not normally distributed data,
Mann–Whitney U-test was performed. In the case of HA, the
adjustment for age was done with Quade’s rank analysis of
covariance. Correlations between HA and lung function param-
eters were determined with Spearman rank correlation. To adjust
correlation between HA and Raw and between HA and ACT for
patients’ age, partial rank correlation was used. AUC values of
Receiver-Operating Characteristics (ROC) were carried out using
standard methods and data are presented as AUC ROC (95% CI).
p values ,0.05 were considered significant in each calculation.
Results
Clinical Characteristics
Median age of asthmatic patients (N= 52) was 35 [29–43.75]
years, whereas FEV1 (% of predicted) 92 [82.5–102], PEF (% of
Hyaluronan Level in Asthma and Asthmatic Pregnancy
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predicted) 90 [75.25–100], and Raw (% of predicted) 127 [102–
165]. ACT total score of 21 [18–24] showed an acceptable level of
disease control resulted by a 450 [0–500] mg daily dose of ICS
(beclomethasone equivalent) used by the patients. Clinical data
and inflammatory parameters of ANP (N=36) and AP (N= 16)
groups are summarized in Table 1. 27 non-pregnant and 12
pregnant patients received ICS treatment. The mean age of
participants was higher in the ANP group compared to the AP
group (41.28 (614.3) vs. 31.13 (65.123), respectively, p = 0.0005).
Sampling was performed in the second or third trimester of
gestation in all pregnant women (delivery data of 5 AP patients
were not available). No difference was detected either in asthma
severity or control or in daily dose of inhaled corticosteroids
between the ANP and AP groups (Table 1).
Comparison of HA Levels between the Two Groups and
its Relationship to Clinical Parameters
Median circulating HA level in all asthmatic patients (N= 52)
was 34.8 [25.6–46.48] ng/mL, and was related to age (p = 0.0064;
r = 0.37). HA values were lower in AP than in ANP subjects (27
[24.7–31.55] vs. 37.4 [30.1–66.55] ng/mL, p= 0.006). After
adjusting for age, significance changed to a trend (p= 0.056)
(Figure 1).
A significant correlation was revealed between HA levels and
Raw (p= 0.0055; r = 0.38; Figure 2) in the whole asthmatic
cohort which remained significant after the adjustment for age
(r = 0.326, p = 0.021); however no relationship was detected
between HA levels and ACT total score, FEV1 or PEF.
Circulating HA was not associated with the daily dose of
inhaled corticosteroids.
In ANP group circulating HA levels were associated with Raw
values (p = 0.004, r = 0.467; Figure 3) and age as well (p = 0.019,
r = 0.39). In the same group an inverse correlation was found
between serum HA levels and ACT total score (p = 0.01, r =2
0.437) (Figure 4). After adjustment for age the association between
HA and Raw (p= 0.014, r = 0.412) as well as between HA and
ACT (p= 0.04, r =20,36) were still present.
In AP patients no major neonatal or maternal complications
were revealed. No correlation was detected between HA and
clinical parameters of asthma or neonatal birth weight. There was
no difference between HA levels of women in the second and the
third trimester (p = 0.27).
Table 1. Clinical data and circulating hyaluronan levels of the four study groups.
ANP (n=36) AP (n =16)
Age (years) 41.28 (614.3) 31.13 (65.123)
Gestational age at sampling (weeks) NA 23.5[17–32.5]
Gestational age at delivery (weeks) NA 38 [38–39]n= 11
Fetal birth weight (grams) NA 3320 [3000–4000]n= 11
FEV1 (% of predicted) 90.5 [82.5–101.5] 94 [82.75–107]
PEF (% of predicted) 94.5 [76.75–100] 87.5 [71.25–96.75]
Raw (% of predicted) 147 [102.3–168] 111 [98–129]
n= 15
ACT total score 21.5 [18–24]n= 34 21 [19–25]n= 15
Daily dose of ICS (beclomethasone equivalent, mg) 500 [0–500] 225 [0–500]
Hyaluronan (HA; ng/mL) 37.4 [30.1–66.55] 27 [24.7–31.55]
ANP – asthmatic non-pregnant; AP – asthmatic pregnant; FEV1– forced expiratory volume in 1 second; PEF – peak expiratory flow rate; Raw – airway resistance; ACT –
Asthma Control Test; ICS – inhaled corticosteroids; NA-not applicable. All p values.0.05 except for age where p = 0.0005.
doi:10.1371/journal.pone.0094678.t001
Figure 1. Circulating HA levels measured in asthmatic preg-
nant and non-pregnant women*. HA – hyaluronic acid; ANP –
asthmatic non-pregnant; AP – asthmatic pregnant; p = 0.006; *data not
adjusted for age.
doi:10.1371/journal.pone.0094678.g001
Figure 2. Correlation between HA levels and airway resistance
in the whole asthmatic cohort. HA – hyaluronic acid; Raw – Airway
Resistance; p = 0.0055; r = 0.38.
doi:10.1371/journal.pone.0094678.g002
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ROC Analysis of HA Values in Controlled and
Uncontrolled Asthma
According to current asthma guidelines ACT total score $20 is
the main determinant of well-controlled asthma. The potential
value of HA in the determination of asthma control was analyzed
using ROC analysis. ROC analyses of HA data were performed in
subgroups of AP, ANP patients and also of all asthmatic patients
with ACT total score above (controlled) and below (uncontrolled)
20. Statistical significance was proved in the case of HA with ACT
score above and below 20 in the ANP group and in the whole
asthmatic cohort.
The area under the receiver operating characteristics curve for
predicting asthma control was 0.826 (95% CI: 0.686–0.966) in the
ANP group. The cut-off value of HA to discriminate between ANP
patients with an ACT score above and below 20 was 37.4 ng/mL
(sensitivity% (95% CI): 80 (51.91–95.67), specificity% (95% CI):
78.95 (54.43–93.95); p = 0.001) (Figure 5).
ROC analysis of HA values in the whole asthmatic patient
group with Asthma Control Test total score above and below 20
yielded an AUC of 0.78 (95% CI: 0.65–0.92) with the 37.4 ng/mL
cut-off value of HA to discriminate between patients with
controlled and not controlled asthma (p = 0.0009, sensitivity%
(95% CI): 70.00 (45.72–88.11), specificity% (95% CI): 82.76
(64.23–94.15) (Figure 6).
Discussion
The aim of this study was to assess serum HA levels in asthmatic
non-pregnant and asthmatic pregnant patients, and to reveal the
possible relationship between HA and asthma control determi-
nants in both groups. To our knowledge, this study was the first to
investigate circulating HA values in asthmatic pregnancy.
The normal circulating concentration of HA may vary from 10
to 100 mg/L [27], and it correlates with age; however the average
level of middle aged persons is between 30–40 mg/L [39]. In line
with this, our data show a median circulating HA level of 34.8 mg/
L in treated, mostly controlled asthmatics and support the
correlation of circulating HA levels with age also in asthma.
However one weakness of this study is the difference between the
age in pregnant and non-pregnant groups.
Interestingly, lower level of circulating HA was found in
asthmatic pregnant women compared to asthmatic non-pregnant
patients in this study. Although the difference failed to reach
statistical significance after correction for age, a trend still
remained. Despite the well-known role of HA in morphogenesis,
Figure 3. Correlation between HA levels and airway resistance
in the asthmatic non-pregnant group. HA – hyaluronic acid; Raw –
Airway Resistance; p = 0.004; r = 0.467.
doi:10.1371/journal.pone.0094678.g003
Figure 4. Negative correlation between HA levels and ACT total
scores in the asthmatic non-pregnant group. HA – hyaluronic
acid; ACT – Asthma Control Test; p = 0.01; r =20.437.
doi:10.1371/journal.pone.0094678.g004
Figure 5. ROC analysis of HA values in asthmatic non-pregnant
patients with controlled and uncontrolled disease according to
ACT total score. HA – hyaluronic acid; ACT – asthma control test.
doi:10.1371/journal.pone.0094678.g005
Figure 6. ROC analysis of HA values in the whole asthmatic
cohort with controlled and uncontrolled disease according to
ACT total score. HA – hyaluronic acid; ACT – asthma control test.
doi:10.1371/journal.pone.0094678.g006
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data on serum HA during pregnancy are not fully concordant.
Kobayashi et al. observed increased serum HA levels in the third
trimester of human pregnancy, especially close to term and a
further increase was seen in labor suggesting an association with
cervical ripening [35]. Elevated HA levels were also seen during
pregnancy complicated with preeclampsia [36]. In our study HA
levels were lower in pregnant than non-pregnant treated asthmatic
patients. Asthma is known to be associated with systemic
inflammation related to lung function and clinical symptoms [1].
Pregnancy on the other hand is characterized by immune
tolerance resulting in attenuation of immunological responses
[18]. Considerable amount of data supports that impaired
maternal tolerance is responsible for adverse neonatal outcomes
in gestations complicated with uncontrolled asthma, and that
restored immune tolerance may help to maintain uncomplicated
gestation in asthmatic women [40]. Therefore, it may be
speculated that decrease in circulating HA level in pregnant
group in this study (regardless of the presence of treated, mostly
controlled asthma) was partially resulted by the immune tolerance
characterizing pregnancy. The other cause may be pregnancy
induced hemodilution [41]. However, lack of healthy pregnant
and non-pregnant control values is a limitation of our study,
though normal circulating HA levels of healthy non-pregnant
people are known [42].
During tissue injury, repair, fibrosis and inflammation, HA
levels elevate both in serum and tissue fluids [43]. Serum HA
concentrations were shown to be comparable in small studies done
on asthmatic and wheezing children [44] and asthmatic and
healthy adults [45]; however it must be noted that available data
on circulating HA concentrations in asthma are scarce. While the
absence of healthy controls is a limitation of our study, it can be
noted that our results show HA levels comparable to published
normal values of subjects of similar age [39]. On the other hand,
although HA values were within the normal range, they were
positively associated to airway resistance and negatively related to
asthma control. HA is involved in asthmatic inflammation in many
ways including the regulation of airway remodeling which is
characterized by airway muscle hyperplasia, increased mucus
production and subepithelial fibrosis thus leading to thickened
airway walls and narrowed airway calibers [46]. Airway resistance
is an important tool in both the diagnosis and management of
asthma, as it is an indicator of airway hyperresponsiveness and
may reflect the airway remodeling process. Hence, based on the
relationship between circulating HA level and Raw, serum HA
assessment may help to estimate airway remodeling in asthma.
The potential value of circulating HA measurement in the
determination of asthma control was analyzed using ROC
analysis. We found that a cut-off level of 37.4 ng/mL is suitable
to discriminate with acceptable sensitivity and specificity between
patients suffering from well-controlled or uncontrolled asthma and
thus help to identify patients with impaired asthma control;
however the diagnostic yield of HA for the detection of
uncontrolled asthma was much lower in asthmatic pregnancy.
In summary, circulating HA seems to be a marker of disease
control in asthma, as it correlates with airway resistance and
effectively discriminates between well-controlled and uncontrolled
asthma. The best utility of HA serving as a screening tool in the
evaluation of asthma control was detected in non-pregnant
patients. Decreased level of HA in asthmatic pregnant women is
presumably the result of pregnancy induced immune tolerance
and attenuated systemic inflammatory responses which weaken
the probable value of serum HA as a marker of asthma control
during pregnancy.
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